Russell Investments Group
IBRX icon

Russell Investments Group’s ImmunityBio IBRX Stock Holding History

Russell Investments Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
115,567
+23,019
+25% +$174K ﹤0.01% 2458
2026
Q1 		$710K Buy
92,548
+70,590
+321% +$483K ﹤0.01% 2377
2025
Q4 		$43.5K Sell
21,958
-2,695
-11% -$6.11K ﹤0.01% 3353
2025
Q3 		$60.6K Buy
24,653
+21,748
+749% +$56K ﹤0.01% 3201
2025
Q2 		$7.67K Sell
2,905
-2,742
-49% -$7.37K ﹤0.01% 3379
2025
Q1 		$17K Buy
5,647
+2,349
+71% +$7.12K ﹤0.01% 3140
2024
Q4 		$8.44K Sell
3,298
-6,318
-66% -$26.3K ﹤0.01% 3176
2024
Q3 		$35.8K Buy
9,616
+1,199
+14% +$5.55K ﹤0.01% 2846
2024
Q2 		$53.2K Buy
8,417
+5,512
+190% +$36.3K ﹤0.01% 2750
2024
Q1 		$15.6K Sell
2,905
-11,861
-80% -$53.7K ﹤0.01% 2801
2023
Q4 		$74.1K Buy
14,766
+11,861
+408% +$37.2K ﹤0.01% 2598
2023
Q3 		$4.91K Hold
2,905
– – ﹤0.01% 3146
2023
Q2 		$8.08K Hold
2,905
– – ﹤0.01% 3009
2023
Q1 		$5.29K Buy
+2,905
New +$9.03K ﹤0.01% 2941
2022
Q1 		– Sell
-113,723
Closed -$691K – 2837
2021
Q4 		$691K Buy
113,723
+32,502
+40% +$244K ﹤0.01% 2323
2021
Q3 		$791K Buy
81,221
+78,738
+3,171% +$866K ﹤0.01% 2286
2021
Q2 		$35K Sell
2,483
-138,119
-98% -$2.28M ﹤0.01% 3157
2021
Q1 		$3.34M Sell
140,602
-40,091
-22% -$1.04M 0.01% 1571
2020
Q4 		$2.41M Buy
180,693
+73,812
+69% +$710K ﹤0.01% 1655
2020
Q3 		$741K Buy
+106,881
New +$1.07M ﹤0.01% 2209
2018
Q4 		– Sell
-17,100
Closed -$63K – 2971
2018
Q3 		$63K Sell
17,100
-700
-4% -$2.21K ﹤0.01% 2810
2018
Q2 		$54K Buy
+17,800
New +$65.9K ﹤0.01% 2801
2017
Q4 		– Sell
-25,320
Closed -$139K – 2976
2017
Q3 		$139K Buy
+25,320
New +$156K ﹤0.01% 2731
2017
Q2 		– Sell
-21,330
Closed -$76K – 2990
2017
Q1 		$76K Buy
+21,330
New +$105K ﹤0.01% 2851

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Russell Investments Group's IBRX Position: Q2 2026 in Review

Russell Investments Group increased its ImmunityBio (IBRX) stake by 25% in Q2 2026, buying an estimated $174K and bringing the position to 115,567 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2458.

Russell Investments Group first reported a position in IBRX in Q1 2017 and has held it in 24 quarters since. The position peaked at $3.34M in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Russell Investments Group held 115,567 shares of ImmunityBio worth $1.01M as of Q2 2026.
  • Russell Investments Group bought 23,019 ImmunityBio shares in Q2 2026, an estimated $174K.
  • ImmunityBio made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2458 holding.
  • Russell Investments Group first reported a position in ImmunityBio in Q1 2017 and has held it in 24 quarters since.
  • Russell Investments Group's ImmunityBio position peaked at $3.34M in Q1 2021.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.